In various tumor entities such as gastric cancer, ovarian cancer, endometrial carcinoma, lung cancer, and osteosarcoma, expression of Fer1L4 was found to be decreased [12–16], whereas upregulation was reported in human glioblastoma and breast cancer [17, 18]. Here, FER1L4 is linked to neoplasm.